This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Clinical Data, Mannkind and Thanks!

Stocks in this article: CLDA MNKD DEPO DCTH PFE ABT

BOSTON ( TheStreet) -- This is the last Biotech Stock Mailbag column in 2010. Call me a slacker but I'm exercising my right to give the Mailbag a much-needed holiday rest.

Before I get to your biotech stock questions and comments, let me take this opportunity to thank all of you for making the Mailbag -- now entering its fifth (!) year -- such an meaningful anchor in TheStreet's coverage of the biotech sector.

My personal feelings about the Mailbag and pretty much everything I try to do at TheStreet were summed up best in a recent email I received from David K.:

"I wanted to thank you again for replying to my comments in this week's Biotech Stock Mailbag article. Even if I don't always agree with your opinions or presentation of information, I am interested in what you have to contribute and I keep abreast of your work daily. One of the first items I read every morning is your column.

"I believe that you taking the time to interact with readers in the comments section of your articles or in a live discussion during panel hearings says a great deal about your work ethic. You are surely committed to providing readers, both friends and foes alike, an opportunity to actually be a part of your column. You create a sense of community (even if a hostile one) through making your column dynamic as opposed to other authors whose static blogs simply post an article and nothing more. Your efforts are commendable and I encourage you to keep up the good work."

Makes me blush. Thank you, David, for the very kind words, even though I like to think that I'm not the one instigating the hostilities. When pushed, however, I will push back.

I truly appreciate all the readers of this Mailbag, my columns and stories. That includes those of you who desperately need spell check (once again, it's l-o-s-e-r, not l-o-o-s-e-r) and even the die-hard conspiracy theorists who will never stop believing that I'm banking coin from hedge fund short sellers in an offshore account.

I get up every day and go to sleep every night trying to provide the best biotech coverage and commentary possible. Integral to that effort is being as interactive with you as I can, whether it's through columns like the Mailbag, live blogs, the commenting section of this web site, email or on Twitter. I want to help you make sense of this crazy, volatile biotech scene in which we're all so interested. The constant feedback, questions and comments you provide -- whether it's filled with praise or stinging with criticism -- are an invaluable and essential part of the equation.

Thanks again for spending another year with me. Happy Holidays and Happy New Year! Now, onto your emails:

My column elucidating the bear thesis on Clinical Data (CLDA) and its anti-depressant vilazodone prompted a response from the bulls.

Wedbush analyst Greg Wade, contrary to my hedge fund source, strongly believes FDA approves vilazodone on Jan. 22 and that the drug's peak sales will top $2 billion.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs